What is Bionano Genomics' operating income?

Bionano Genomics' total operating income in 2025 was -$33.34 million, based on the following breakdown: Total Gross Profit: $13.19 million Total Operating Expenses: $46.52 million

Bionano Genomics (BNGO) Financials

$1.00 -0.04 (-3.85%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$1.01 +0.01 (+1.40%)

As of 11/13/2026 07:56 PM Eastern

Compare

Annual Income Statements for Bionano Genomics

This table shows Bionano Genomics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-23	-18	-30	-41	-72	-133	-232	-112	-26
Consolidated Net Income / (Loss)	-23	-18	-30	-41	-72	-133	-232	-112	-26
Net Income / (Loss) Continuing Operations	-23	-18	-30	-41	-72	-133	-232	-112	-26
Total Pre-Tax Income	-23	-18	-30	-41	-78	-131	-232	-112	-26
Total Operating Income	-23	-20	-26	-39	-77	-132	-215	-104	-33
Total Gross Profit	3.47	3.29	3.36	2.77	3.87	5.95	9.57	0.38	13
Total Revenue	9.51	12	10	8.50	18	28	36	31	29
Operating Revenue	9.51	12	10	8.50	18	28	36	31	29
Total Cost of Revenue	6.03	8.71	6.77	5.73	14	22	27	30	15
Operating Cost of Revenue	6.03	8.71	6.77	5.73	14	22	27	30	15
Total Operating Expenses	27	24	29	41	81	138	225	104	47
Selling, General & Admin Expense	14	14	20	31	58	89	93	52	35
Research & Development Expense	12	9.48	9.08	10	22	49	54	25	11
Impairment Charge	0.60	-	-	-	-	0.00	77	20	0.00
Restructuring Charge	-	-	-	-	-	-	0.74	8.02	0.00
Total Other Income / (Expense), net	-0.13	1.93	-3.92	-2.53	-1.05	0.99	-17	-8.00	7.01
Interest & Investment Income	-	-	-	0.00	0.24	1.51	3.31	2.10	1.11
Other Income / (Expense), net	0.46	3.66	-0.30	-0.01	1.72	-0.22	-20	-10	5.90
Income Tax Expense	0.02	0.02	0.02	0.03	-5.72	1.88	0.06	0.03	0.07
Basic Earnings per Share	($8.65)	($2.61)	($1.99)	($0.39)	($0.26)	($4.58)	($408.60)	($88.13)	($4.85)
Weighted Average Basic Shares Outstanding	2.70M	7.08M	14.98M	104.25M	276.78M	28.92M	569K	1.27M	5.45M
Diluted Earnings per Share	($8.65)	($2.61)	($1.99)	($0.39)	($0.26)	($4.58)	($408.60)	($88.13)	($4.85)
Weighted Average Diluted Shares Outstanding	2.70M	7.08M	14.98M	104.25M	276.78M	28.92M	569K	1.27M	5.45M
Weighted Average Basic & Diluted Shares Outstanding	2.70M	7.08M	14.98M	104.25M	276.78M	306.24M	54.69M	3.01M	11.09M

This table shows Bionano Genomics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026	9/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-31	-16	-44	-20	-3.10	-6.86	-8.50	-7.93	-8.30	-7.42	-6.45
Consolidated Net Income / (Loss)	-31	-16	-44	-20	-3.10	-6.86	-8.50	-7.93	-8.30	-7.42	-6.45
Net Income / (Loss) Continuing Operations	-31	-16	-44	-20	-3.10	-6.86	-8.50	-7.93	-8.30	-7.42	-6.45
Total Pre-Tax Income	-31	-16	-44	-20	-3.10	-6.85	-8.49	-7.90	-8.29	-7.42	-6.45
Total Operating Income	-31	-17	-44	-12	-8.47	-7.80	-8.54	-8.54	-7.90	-7.22	-6.54
Total Gross Profit	2.82	2.59	-8.45	3.42	2.94	3.48	3.37	3.40	3.25	4.31	3.95
Total Revenue	8.77	7.77	6.07	8.16	6.46	6.73	7.37	7.95	6.69	8.17	8.28
Operating Revenue	8.77	7.77	6.07	8.16	6.46	6.73	7.37	7.95	6.69	8.17	8.28
Total Cost of Revenue	5.95	5.19	15	4.75	3.52	3.26	4.00	4.55	3.44	3.86	4.33
Operating Cost of Revenue	5.95	5.19	15	4.75	3.52	3.26	4.00	4.55	3.44	3.86	4.33
Total Operating Expenses	34	20	35	15	11	11	12	12	11	12	10
Selling, General & Admin Expense	19	12	9.46	12	9.03	8.35	9.06	8.71	8.01	8.54	7.44
Research & Development Expense	9.78	6.83	4.72	3.48	2.37	2.93	2.84	3.23	3.14	2.99	3.04
Impairment Charge	0.45	0.00	20	-0.27	0.00	0.00	0.00	-	0.00	0.00	0.00
Restructuring Charge	4.63	1.22	1.77	0.41	0.00	0.00	0.00	-	0.00	0.00	0.00
Total Other Income / (Expense), net	-0.32	0.82	-0.32	-8.18	5.37	0.95	0.05	0.64	-0.40	-0.20	0.09
Interest & Investment Income	1.04	0.46	0.38	0.22	0.29	0.28	0.27	0.28	0.22	0.15	0.06
Other Income / (Expense), net	-1.36	0.36	-0.70	-8.41	5.08	0.68	-0.22	0.36	-0.62	-0.34	0.03
Income Tax Expense	-0.02	0.03	0.02	0.00	0.01	0.01	0.01	0.04	0.01	0.01	0.01
Basic Earnings per Share	($35.75)	($14.41)	($30.92)	($15.83)	($1.15)	($1.99)	($1.59)	($1.46)	($0.76)	($0.64)	($0.54)
Weighted Average Basic Shares Outstanding	879K	1.13M	1.43M	1.27M	2.69M	3.44M	5.34M	5.45M	10.98M	11.55M	11.99M
Diluted Earnings per Share	($35.75)	($14.41)	($30.92)	($15.83)	($1.15)	($1.99)	($1.59)	($1.46)	($0.76)	($0.64)	($0.54)
Weighted Average Diluted Shares Outstanding	879K	1.13M	1.43M	1.27M	2.69M	3.44M	5.34M	5.45M	10.98M	11.55M	11.99M
Weighted Average Basic & Diluted Shares Outstanding	66.86M	86.00M	101.99M	3.01M	3.36M	4.68M	10.18M	11.09M	11.48M	11.78M	13.99M

This table details how cash moves in and out of Bionano Genomics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-4.23	16	0.79	21	-14	-19	13	-8.78	-5.06
Net Cash From Operating Activities	-21	-20	-30	-38	-72	-125	-125	-69	-16
Net Cash From Continuing Operating Activities	-21	-20	-30	-38	-72	-126	-124	-69	-16
Net Income / (Loss) Continuing Operations	-23	-18	-30	-41	-72	-133	-232	-112	-26
Consolidated Net Income / (Loss)	-23	-18	-30	-41	-72	-133	-232	-112	-26
Depreciation Expense	1.50	1.32	1.13	1.48	3.35	9.62	14	14	9.53
Amortization Expense	-	-	-	0.00	0.02	0.86	-0.34	-1.11	-0.77
Non-Cash Adjustments To Reconcile Net Income	0.96	-0.40	4.13	4.75	11	22	111	37	0.78
Changes in Operating Assets and Liabilities, net	0.09	-2.37	-4.97	-3.44	-13	-26	-16	-6.73	0.51
Net Cash From Investing Activities	-1.02	-0.33	-0.06	-2.45	-278	83	24	74	-13
Net Cash From Continuing Investing Activities	-1.02	-0.33	-0.06	-2.45	-278	82	24	74	-13
Purchase of Property, Plant & Equipment	-1.02	-0.33	-0.06	0.00	-0.82	-2.50	-1.69	-0.10	0.00
Purchase of Investments	-	-	-	0.00	-313	-84	-111	-233	-242
Sale and/or Maturity of Investments	-	-	-	0.00	86	201	137	307	229
Net Cash From Financing Activities	18	36	30	62	336	23	114	-14	24
Net Cash From Continuing Financing Activities	18	36	30	62	336	23	114	-14	24
Repayment of Debt	0.00	-7.45	-14	-7.26	-15	0.00	-14	-73	-4.88
Repurchase of Common Equity	-	-	0.00	-2.00	-1.70	-0.58	-1.44	-	-2.12
Issuance of Debt	0.00	24	24	2.54	0.00	0.00	80	18	0.00
Issuance of Common Equity	0.00	19	20	40	343	23	58	41	31
Other Financing Activities, net	0.01	0.00	1.00	29	10	0.31	-9.05	-0.06	-0.07
Effect of Exchange Rate Changes	-	-	-	-	-	-	0.07	-0.01	-0.01
Cash Interest Paid	0.53	0.70	1.28	1.25	1.91	0.30	1.65	11	1.67

This table details how cash moves in and out of Bionano Genomics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026	9/30/2026
Net Change in Cash & Equivalents	-2.19	5.67	-13	0.38	-5.95	-0.06	-0.50	1.44	0.40	-0.68	0.63
Net Cash From Operating Activities	-28	-21	-13	-6.50	-2.76	-3.49	-5.92	-4.18	-5.72	-4.67	-4.52
Net Cash From Continuing Operating Activities	-28	-21	-13	-6.50	-2.76	-3.49	-5.92	-4.18	-5.72	-4.67	-4.52
Net Income / (Loss) Continuing Operations	-31	-16	-44	-20	-3.10	-6.86	-8.50	-7.93	-8.30	-7.42	-6.45
Consolidated Net Income / (Loss)	-31	-16	-44	-20	-3.10	-6.86	-8.50	-7.93	-8.30	-7.42	-6.45
Depreciation Expense	3.01	2.99	5.63	2.40	2.43	2.38	2.38	2.34	2.31	2.30	2.29
Amortization Expense	-0.64	-0.17	-0.21	-0.09	-0.19	-0.20	-0.19	-0.20	-0.14	-0.06	0.02
Non-Cash Adjustments To Reconcile Net Income	-3.69	1.22	30	9.29	-3.93	1.95	1.40	1.36	1.05	1.17	0.42
Changes in Operating Assets and Liabilities, net	4.66	-8.84	-4.58	2.03	2.02	-0.76	-1.01	0.26	-0.63	-0.66	-0.79
Net Cash From Investing Activities	48	29	-5.38	3.00	-14	1.98	-4.67	4.01	5.46	14	2.41
Net Cash From Continuing Investing Activities	48	29	-5.38	3.00	-14	1.98	-4.67	4.01	5.46	14	2.41
Purchase of Investments	-111	-41	-63	-19	-65	-52	-61	-64	-49	-31	-10
Sale and/or Maturity of Investments	158	70	57	22	51	54	56	68	54	45	12
Net Cash From Financing Activities	-22	-1.98	6.02	3.89	11	1.47	10	1.60	0.66	-9.69	2.74
Net Cash From Continuing Financing Activities	-22	-1.98	6.02	3.89	11	1.47	10	1.60	0.66	-9.69	2.74
Repurchase of Common Equity	-0.39	-0.98	-1.08	-	-0.92	-0.10	-0.97	-0.13	-0.03	-0.03	-0.10
Issuance of Common Equity	15	12	10	3.77	13	3.09	13	1.75	0.71	0.62	2.86
Other Financing Activities, net	-0.01	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02
Effect of Exchange Rate Changes	-0.03	-0.00	0.02	-0.00	-0.01	-	0.02	0.01	0.01	0.00	0.00
Cash Interest Paid	5.62	4.05	0.47	0.52	0.48	0.44	0.39	0.36	0.36	0.25	0.07

This table presents Bionano Genomics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	10	25	30	60	377	308	214	77	74
Total Current Assets	7.14	23	28	47	272	157	140	39	45
Cash & Equivalents	1.02	17	17	38	25	5.09	18	9.17	2.99
Restricted Cash	-	-	-	-	-	0.00	35	11	10
Short-Term Investments	-	-	-	0.00	226	108	49	0.30	16
Accounts Receivable	3.35	4.51	6.33	2.78	4.93	7.02	9.32	4.75	5.20
Inventories, net	1.69	1.07	3.44	3.32	12	30	23	11	5.45
Prepaid Expenses	1.07	0.92	1.17	2.25	4.48	7.33	6.02	3.14	5.20
Plant, Property, & Equipment, net	3.01	1.78	1.95	4.91	10	18	23	19	15
Total Noncurrent Assets	0.00	0.00	0.00	8.75	94	132	51	18	13
Noncurrent Note & Lease Receivables	-	-	-	-	3.93	3.71	3.50	3.30	3.10
Intangible Assets	-	-	0.00	1.48	27	41	34	9.71	4.35
Other Noncurrent Operating Assets	-	-	0.00	0.10	7.44	10	13	4.96	5.91
Total Liabilities & Shareholders' Equity	10	25	30	60	377	308	214	77	74
Total Liabilities	17	15	27	25	40	58	118	41	29
Total Current Liabilities	17	4.52	26	8.95	22	36	100	37	23
Accounts Payable	2.30	1.35	2.70	2.93	11	13	10	6.96	5.59
Accrued Expenses	3.51	2.90	3.23	5.60	8.62	11	8.09	5.64	5.46
Current Deferred Revenue	0.21	0.27	0.36	0.42	0.68	0.87	0.78	1.13	0.97
Other Current Liabilities	3.90	-	-	-	1.77	2.55	81	24	11
Total Noncurrent Liabilities	0.71	10	0.23	16	18	22	18	3.95	6.22
Noncurrent Deferred Revenue	0.14	0.30	0.18	0.10	0.15	0.13	0.15	0.27	0.25
Other Noncurrent Operating Liabilities	0.57	0.81	0.04	-	18	22	18	3.68	5.97
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-50	10	3.61	35	337	249	96	35	44
Total Preferred & Common Equity	-50	10	3.61	35	337	249	96	35	44
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-50	10	3.61	35	337	249	96	35	44
Common Stock	4.04	83	106	179	554	599	677	729	764
Retained Earnings	-54	-73	-103	-144	-216	-349	-581	-693	-720
Accumulated Other Comprehensive Income / (Loss)	-	-	-	0.00	-0.54	-1.12	0.02	0.03	0.02

This table presents Bionano Genomics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026	9/30/2026
Total Assets	182	158	129	87	78	76	79	65	48	46
Total Current Assets	105	86	61	47	45	43	49	39	25	26
Cash & Equivalents	35	16	10	8.79	3.63	3.56	3.07	3.43	3.73	4.36
Restricted Cash	-	24	11	11	11	11	10	10	0.50	0.50
Short-Term Investments	29	13	8.52	3.16	15	13	19	11	6.19	3.81
Accounts Receivable	8.67	8.31	6.26	5.32	3.35	3.49	4.53	4.13	4.37	5.85
Inventories, net	26	20	19	14	9.56	8.63	7.05	5.31	5.20	6.51
Prepaid Expenses	5.86	4.95	4.89	4.39	2.78	3.10	5.38	4.86	4.89	4.48
Plant, Property, & Equipment, net	21	25	25	20	18	17	16	14	13	12
Total Noncurrent Assets	56	47	44	20	15	16	14	12	9.70	8.54
Noncurrent Note & Lease Receivables	3.56	3.45	3.40	3.35	3.25	3.20	3.15	3.04	2.99	2.94
Intangible Assets	36	32	30	11	8.37	7.03	5.69	3.01	1.67	0.33
Other Noncurrent Operating Assets	17	12	11	5.99	3.53	5.86	5.26	5.74	5.04	5.28
Total Liabilities & Shareholders' Equity	182	158	129	87	78	76	79	65	48	46
Total Liabilities	63	75	49	38	30	31	29	27	16	18
Total Current Liabilities	40	59	37	33	26	24	23	21	10	12
Accounts Payable	15	9.84	8.73	8.70	6.56	6.24	5.99	5.06	4.56	5.54
Accrued Expenses	12	11	5.53	5.88	3.94	3.41	4.71	4.00	3.46	4.78
Current Deferred Revenue	0.81	1.04	1.15	1.20	1.02	1.17	1.18	1.13	1.15	1.12
Other Current Liabilities	2.46	37	22	17	15	13	11	11	0.88	0.86
Total Noncurrent Liabilities	23	17	12	5.54	3.82	6.46	6.29	6.11	5.95	5.77
Noncurrent Deferred Revenue	0.15	0.14	0.27	0.26	0.29	0.24	0.19	0.14	0.12	0.09
Other Noncurrent Operating Liabilities	23	17	12	5.28	3.53	6.22	6.09	5.97	5.83	5.68
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	119	83	80	49	48	45	50	37	32	28
Total Preferred & Common Equity	119	83	80	49	48	45	50	37	32	28
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	119	83	80	49	48	45	50	37	32	28
Common Stock	656	695	709	720	745	749	761	765	767	770
Retained Earnings	-537	-613	-629	-673	-696	-703	-712	-728	-735	-742
Accumulated Other Comprehensive Income / (Loss)	-0.09	-0.02	-0.00	1.53	0.01	-0.01	0.01	0.01	0.01	0.01

This table displays calculated financial ratios and metrics derived from Bionano Genomics' official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	10,032,687.00	26,489,740.00	153,186,000.00	289,184,109.00	296,924,500.00	38,840,337.00	101,993,225.00	10,176,000.00
DEI Adjusted Shares Outstanding	0.00	16,721.00	44,150.00	255,310.00	481,974.00	494,874.00	647,339.00	1,699,887.00	10,176,000.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-1,106.18	-675.31	-161.00	-150.29	-267.94	-359.15	-65.90	-2.59
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	26.26%	-15.59%	-16.06%	111.47%	54.62%	29.90%	-14.79%	-7.37%
EBITDA Growth	0.00%	27.36%	-62.25%	-48.04%	-94.22%	-68.64%	-83.11%	54.50%	81.53%
EBIT Growth	0.00%	26.36%	-56.19%	-47.31%	-95.51%	-75.00%	-78.70%	51.61%	75.95%
NOPAT Growth	0.00%	12.08%	-26.74%	-48.99%	-100.00%	-70.81%	-63.44%	51.69%	67.94%
Net Income Growth	0.00%	20.84%	-61.19%	-37.87%	-76.22%	-83.06%	-75.34%	51.82%	76.44%
EPS Growth	0.00%	69.83%	23.75%	80.40%	33.33%	-83.06%	-75.34%	51.82%	94.50%
Operating Cash Flow Growth	0.00%	4.20%	-48.06%	-29.75%	-87.73%	-73.53%	-0.29%	44.94%	76.28%
Free Cash Flow Firm Growth	0.00%	0.00%	-18.50%	-53.54%	-280.01%	-18.63%	100.43%	-14,395.20%	75.03%
Invested Capital Growth	0.00%	275.19%	141.58%	102.87%	567.59%	68.31%	-103.94%	359.99%	-0.07%
Revenue Q/Q Growth	0.00%	0.00%	-10.79%	16.44%	14.76%	7.39%	7.46%	-7.67%	-0.74%
EBITDA Q/Q Growth	0.00%	0.00%	-3.32%	-11.33%	-29.26%	-7.00%	-3.23%	19.00%	39.12%
EBIT Q/Q Growth	0.00%	0.00%	-3.84%	-11.67%	-30.49%	-7.16%	-3.34%	17.88%	30.73%
NOPAT Q/Q Growth	0.00%	0.00%	-4.28%	-11.47%	-29.70%	-7.11%	5.52%	11.12%	9.27%
Net Income Q/Q Growth	0.00%	0.00%	-5.26%	-10.27%	-18.33%	-13.46%	-2.29%	17.50%	31.60%
EPS Q/Q Growth	0.00%	0.00%	-4.19%	-39.29%	-18.18%	-13.46%	-2.29%	17.50%	32.92%
Operating Cash Flow Q/Q Growth	0.00%	-6.86%	-21.83%	-7.65%	-23.14%	-7.67%	3.65%	25.24%	12.47%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-5.18%	-181.60%	16.62%	100.57%	-120.37%	-31.35%
Invested Capital Q/Q Growth	0.00%	0.00%	54.76%	9.60%	458.25%	31.34%	-108.76%	-42.50%	-17.06%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	36.55%	27.41%	33.18%	32.61%	21.55%	21.38%	26.49%	1.23%	46.25%
EBITDA Margin	-223.58%	-128.64%	-247.26%	-436.07%	-400.51%	-436.81%	-615.71%	-328.75%	-65.54%
Operating Margin	-244.28%	-170.12%	-255.44%	-453.38%	-428.79%	-473.70%	-595.98%	-337.87%	-116.95%
EBIT Margin	-239.41%	-139.64%	-258.40%	-453.46%	-419.25%	-474.50%	-652.74%	-370.69%	-96.25%
Profit (Net Income) Margin	-245.82%	-154.13%	-294.34%	-483.43%	-402.84%	-476.93%	-643.74%	-363.98%	-92.59%
Tax Burden Percent	100.08%	100.08%	100.07%	100.07%	92.68%	101.44%	100.03%	100.03%	100.25%
Interest Burden Percent	102.60%	110.28%	113.83%	106.53%	103.67%	99.08%	98.60%	98.16%	95.95%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-2,518.66%	-401.10%	-278.99%	-108.52%	-79.44%	-215.46%	-1,587.70%	-156.68%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-2,047.55%	94.79%	-133.05%	-94.98%	-56.64%	-135.90%	-1,523.58%	-144.46%
Return on Net Nonoperating Assets (RNNOA)	0.00%	1,251.90%	-32.54%	66.53%	69.60%	34.22%	80.89%	1,417.37%	90.53%
Return on Equity (ROE)	323.75%	-1,266.76%	-433.64%	-212.46%	-38.92%	-45.21%	-134.56%	-170.33%	-66.15%
Cash Return on Invested Capital (CROIC)	0.00%	-697.57%	-484.00%	-346.92%	-256.41%	-130.35%	0.00%	-626.97%	-156.61%
Operating Return on Assets (OROA)	-224.30%	-95.90%	-95.16%	-85.06%	-34.46%	-38.54%	-90.34%	-78.39%	-36.52%
Return on Assets (ROA)	-230.31%	-105.85%	-108.40%	-90.68%	-33.11%	-38.74%	-89.09%	-76.97%	-35.13%
Return on Common Equity (ROCE)	2,253.15%	17,390.16%	-433.64%	-212.46%	-38.92%	-45.21%	-134.56%	-170.33%	-66.15%
Return on Equity Simple (ROE_SIMPLE)	46.52%	-182.46%	-825.05%	-117.17%	-21.49%	-53.17%	-241.78%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-16	-14	-18	-27	-54	-92	-151	-73	-23
NOPAT Margin	-171.00%	-119.08%	-178.81%	-317.37%	-300.15%	-331.59%	-417.19%	-236.51%	-81.86%
Net Nonoperating Expense Percent (NNEP)	124.60%	-471.11%	-495.90%	-145.94%	-13.54%	-22.80%	-79.56%	-64.12%	-12.23%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-156.69%	-205.76%	-52.53%
Cost of Revenue to Revenue	63.45%	72.59%	66.82%	67.39%	78.46%	78.62%	73.51%	98.77%	53.75%
SG&A Expenses to Revenue	148.13%	118.50%	198.98%	365.38%	325.29%	318.67%	256.83%	168.49%	123.30%
R&D to Revenue	126.35%	79.03%	89.65%	120.62%	125.05%	176.42%	149.61%	80.59%	39.90%
Operating Expenses to Revenue	280.83%	197.53%	288.62%	485.99%	450.34%	495.08%	622.47%	339.11%	163.20%
Earnings before Interest and Taxes (EBIT)	-23	-17	-26	-39	-75	-132	-236	-114	-27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-21	-15	-25	-37	-72	-121	-222	-101	-19
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	5.19	9.09	13.45	2.56	1.74	0.76	0.83	0.35
Price to Tangible Book Value (P/TBV)	0.00	5.19	9.09	17.85	3.40	3.31	1.18	1.15	0.39
Price to Revenue (P/Rev)	2.17	4.38	3.24	55.49	48.09	15.59	2.03	0.96	0.55
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	17.05	5.58	34.70	7.10	2.26	0.00	0.60	0.00
Enterprise Value to Revenue (EV/Rev)	7.29	3.76	3.52	52.89	34.15	11.86	0.00	0.29	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	-0.93	0.89	5.56	0.47	0.00	0.04	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.89	0.00	0.47	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.79	-0.61	-0.34	-0.50	-0.73	-0.60	-0.60	-0.93	-0.63
Leverage Ratio	-1.41	11.97	4.00	2.34	1.18	1.17	1.51	2.21	1.88
Compound Leverage Factor	-1.44	13.20	4.55	2.50	1.22	1.16	1.49	2.17	1.81
Debt to Total Capital	-1,380.97%	47.11%	84.75%	31.76%	0.00%	3.63%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	-1,380.97%	0.00%	84.75%	0.00%	0.00%	3.63%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	47.11%	0.00%	31.76%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-8,825.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	10,306.78%	52.89%	15.25%	68.24%	100.00%	96.37%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.32	-0.58	-0.80	-0.44	0.00	-0.08	0.00	0.00	0.00
Net Debt to EBITDA	-0.27	0.49	-0.11	0.60	0.00	0.85	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.58	0.00	-0.44	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.41	-0.63	-1.11	-0.61	0.00	-0.10	0.00	0.00	0.00
Net Debt to NOPAT	-0.35	0.52	-0.15	0.82	0.00	1.13	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.63	0.00	-0.61	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-14.37	-2.81	-6.46	6.62	12.36	2.04	-6.66	-16.71	-13.85
Noncontrolling Interest Sharing Ratio	-595.95%	1,472.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.43	5.09	1.07	5.23	12.47	4.38	1.40	1.06	1.98
Quick Ratio	0.26	4.65	0.90	4.61	11.70	3.35	0.76	0.38	1.07
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-18	-22	-34	-128	-151	0.65	-93	-23
Operating Cash Flow to CapEx	-2,045.31%	-6,012.33%	-48,364.98%	0.00%	-8,750.24%	-5,049.19%	-7,402.78%	-66,914.56%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-10.70	-6.04	-13.32	-42.46	-507.64	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-35.23	-11.57	-8.16	-15.21	-23.95	-418.85	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-36.95	-11.77	-8.17	-15.21	-24.23	-427.14	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.94	0.69	0.37	0.19	0.08	0.08	0.14	0.21	0.38
Accounts Receivable Turnover	2.84	3.05	1.87	1.87	4.66	4.65	4.42	4.37	5.73
Inventory Turnover	3.56	6.31	3.00	1.70	1.80	1.04	1.01	1.79	1.85
Fixed Asset Turnover	3.16	5.02	5.44	2.48	2.36	1.96	1.75	1.45	1.67
Accounts Payable Turnover	2.62	4.77	3.34	2.04	2.06	1.88	2.32	3.50	2.44
Days Sales Outstanding (DSO)	128.73	119.63	195.45	195.51	78.24	78.48	82.57	83.44	63.71
Days Inventory Outstanding (DIO)	102.51	57.87	121.67	215.26	203.13	351.92	361.93	204.22	197.34
Days Payable Outstanding (DPO)	139.39	76.57	109.23	179.29	177.22	194.57	157.53	104.15	149.50
Cash Conversion Cycle (CCC)	91.85	100.93	207.89	231.48	104.16	235.83	286.97	183.51	111.55
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	-1.51	2.64	6.39	13	87	146	-5.73	15	15
Invested Capital Turnover	-6.30	21.15	2.24	0.88	0.36	0.24	0.52	6.71	1.91
Increase / (Decrease) in Invested Capital	0.00	4.15	3.74	6.57	74	59	-151	21	-0.01
Enterprise Value (EV)	69	45	36	450	614	330	-28	8.94	-14
Market Capitalization	21	53	33	472	865	434	73	29	16
Book Value per Share	($18.60)	$1.01	$0.14	$0.23	$1.17	$0.84	$2.48	$0.35	$4.37
Tangible Book Value per Share	($18.60)	$1.01	$0.14	$0.17	$0.88	$0.44	$1.60	$0.25	$3.94
Total Capital	-0.49	19	24	51	337	259	96	35	44
Total Debt	6.73	9.03	20	16	0.00	9.38	0.00	0.00	0.00
Total Long-Term Debt	0.00	9.03	0.00	16	0.00	0.00	0.00	0.00	0.00
Net Debt	5.71	-7.49	2.77	-22	-251	-104	-102	-20	-30
Capital Expenditures (CapEx)	1.02	0.33	0.06	0.00	0.82	2.47	1.69	0.10	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-3.81	1.98	4.66	-0.61	-0.04	18	-62	-18	-7.09
Debt-free Net Working Capital (DFNWC)	-2.78	19	22	38	251	131	40	2.15	22
Net Working Capital (NWC)	-9.51	19	1.89	38	251	121	40	2.15	22
Net Nonoperating Expense (NNE)	7.11	4.21	12	14	18	40	82	39	3.06
Net Nonoperating Obligations (NNO)	5.71	-7.49	2.77	-22	-251	-104	-102	-20	-30
Total Depreciation and Amortization (D&A)	1.50	1.32	1.13	1.48	3.37	10	13	13	8.76
Debt-free, Cash-free Net Working Capital to Revenue	-40.03%	16.50%	46.05%	-7.12%	-0.21%	63.34%	-171.11%	-59.56%	-24.87%
Debt-free Net Working Capital to Revenue	-29.28%	154.18%	216.95%	445.07%	1,393.55%	470.46%	111.00%	6.97%	78.73%
Net Working Capital to Revenue	-100.08%	154.18%	18.67%	445.07%	1,393.55%	436.71%	111.00%	6.97%	78.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($86.50)	($26.10)	($19.90)	($3.90)	($2.60)	($4.60)	($408.60)	($88.13)	($4.85)
Adjusted Weighted Average Basic Shares Outstanding	270.11K	1.01M	3.78M	27.87M	28.96M	28.92M	569.17K	1.27M	5.45M
Adjusted Diluted Earnings per Share	($86.50)	($26.10)	($19.90)	($3.90)	($2.60)	($4.60)	($408.60)	($88.13)	($4.85)
Adjusted Weighted Average Diluted Shares Outstanding	270.11K	1.01M	3.78M	27.87M	28.96M	28.92M	569.17K	1.27M	5.45M
Adjusted Basic & Diluted Earnings per Share	($86.50)	($26.10)	($19.90)	($3.90)	($2.60)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	270.11K	707.71K	1.50M	10.43M	27.68M	30.62M	911.57K	3.01M	11.09M
Normalized Net Operating Profit after Tax (NOPAT)	-16	-14	-18	-27	-54	-92	-96	-53	-23
Normalized NOPAT Margin	-166.54%	-119.08%	-178.81%	-317.37%	-300.15%	-331.59%	-265.97%	-173.49%	-81.86%
Pre Tax Income Margin	-245.63%	-154.00%	-294.13%	-483.09%	-434.64%	-470.15%	-643.57%	-363.87%	-92.35%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-38.51	-9.72	-7.23	-15.31	-25.10	-442.69	0.00	0.00	0.00
NOPAT to Interest Expense	-27.50	-8.29	-5.00	-10.71	-17.97	-309.36	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-40.23	-9.92	-7.25	-15.31	-25.38	-450.98	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-29.23	-8.49	-5.02	-10.71	-18.25	-317.65	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-4.87%	-2.35%	-0.44%	-0.62%	0.00%	-8.04%

This table displays calculated financial ratios and metrics derived from Bionano Genomics' official financial filings.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026	9/30/2026
DEI Shares Outstanding	54,694,000.00	66,856,804.00	85,997,130.00	101,993,225.00	3,007,000.00	3,364,000.00	4,681,000.00	10,176,000.00	11,092,000.00	11,475,000.00	11,777,000.00
DEI Adjusted Shares Outstanding	911,567.00	1,114,280.00	1,433,286.00	1,699,887.00	3,007,000.00	3,364,000.00	4,681,000.00	10,176,000.00	11,092,000.00	11,475,000.00	11,777,000.00
DEI Earnings Per Adjusted Shares Outstanding	-34.47	-14.56	-30.87	-11.84	-1.03	-2.04	-1.82	-0.78	-0.75	-0.65	-0.55
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	18.26%	-10.29%	-34.83%	-23.86%	-26.37%	-13.36%	21.31%	-2.60%	3.56%	21.36%	12.34%
EBITDA Growth	12.86%	61.96%	64.27%	56.82%	96.21%	64.28%	83.24%	66.55%	-455.95%	-7.73%	35.96%
EBIT Growth	13.89%	57.91%	60.62%	54.97%	89.58%	57.23%	80.36%	59.83%	-151.58%	-6.15%	25.68%
NOPAT Growth	17.76%	56.63%	61.22%	52.14%	72.80%	54.17%	80.55%	28.52%	6.71%	7.46%	23.45%
Net Income Growth	15.36%	58.31%	60.69%	54.15%	90.13%	57.74%	80.78%	60.58%	-167.67%	-8.25%	24.11%
EPS Growth	15.36%	58.31%	60.69%	54.15%	96.78%	86.19%	94.86%	90.78%	33.91%	67.84%	66.04%
Operating Cash Flow Growth	13.21%	42.83%	49.38%	78.16%	90.17%	83.38%	55.53%	35.81%	-106.80%	-33.93%	23.57%
Free Cash Flow Firm Growth	221.37%	224.59%	125.95%	-121.66%	-94.51%	-68.39%	-77.37%	79.43%	-87.56%	-130.76%	-410.48%
Invested Capital Growth	-79.33%	-65.88%	-60.39%	359.99%	-36.82%	-64.40%	-30.72%	-0.07%	-32.52%	18.12%	8.85%
Revenue Q/Q Growth	-18.21%	-11.38%	-21.85%	34.41%	-20.90%	4.27%	9.42%	7.93%	-15.90%	22.19%	1.29%
EBITDA Q/Q Growth	27.90%	54.07%	-183.23%	53.96%	93.67%	-332.75%	-32.86%	8.10%	-5.22%	16.14%	21.02%
EBIT Q/Q Growth	28.12%	48.73%	-167.78%	54.37%	83.36%	-110.46%	-22.92%	6.67%	-4.20%	11.20%	13.94%
NOPAT Q/Q Growth	-24.73%	45.32%	-157.97%	72.80%	29.11%	7.86%	-9.46%	0.02%	7.49%	8.60%	9.45%
Net Income Q/Q Growth	28.41%	48.37%	-172.72%	54.52%	84.59%	-121.05%	-24.00%	6.70%	-4.66%	10.60%	13.07%
EPS Q/Q Growth	28.41%	48.37%	-172.72%	54.52%	92.74%	-73.04%	20.10%	8.18%	47.95%	15.79%	15.63%
Operating Cash Flow Q/Q Growth	5.53%	25.43%	36.56%	51.13%	57.50%	-26.16%	-69.74%	29.46%	-36.91%	18.30%	3.13%
Free Cash Flow Firm Q/Q Growth	-30.26%	-8.52%	-89.73%	-430.47%	117.67%	426.93%	-92.64%	-400.40%	110.68%	-1,403.19%	25.76%
Invested Capital Q/Q Growth	623.56%	67.93%	-48.57%	-42.50%	27.23%	-5.39%	0.09%	-17.06%	-14.08%	65.62%	-7.76%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	32.20%	33.26%	-139.07%	41.86%	45.50%	51.64%	45.74%	42.76%	48.63%	52.80%	47.72%
EBITDA Margin	-343.48%	-178.02%	-645.18%	-220.98%	-17.69%	-73.40%	-89.13%	-75.89%	-94.95%	-65.16%	-50.81%
Operating Margin	-354.92%	-218.99%	-722.89%	-146.28%	-131.10%	-115.85%	-115.90%	-107.36%	-118.09%	-88.34%	-78.98%
EBIT Margin	-370.44%	-214.32%	-734.37%	-249.27%	-52.42%	-105.81%	-118.87%	-102.79%	-127.35%	-92.55%	-78.64%
Profit (Net Income) Margin	-358.33%	-208.78%	-728.57%	-246.54%	-48.04%	-101.84%	-115.42%	-99.77%	-124.17%	-90.85%	-77.97%
Tax Burden Percent	99.94%	100.16%	100.05%	100.01%	100.23%	100.15%	100.16%	100.46%	100.12%	100.09%	100.12%
Interest Burden Percent	96.79%	97.26%	99.16%	98.90%	91.43%	96.11%	96.94%	96.62%	97.38%	98.07%	99.03%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-106.30%	-56.62%	-369.38%	-687.40%	-106.70%	-65.10%	-106.23%	-143.84%	-149.65%	-95.39%	-91.67%
ROIC Less NNEP Spread (ROIC-NNEP)	-92.45%	-47.73%	-334.06%	-668.17%	-113.59%	-60.23%	-97.01%	-136.01%	-139.36%	-82.87%	-82.40%
Return on Net Nonoperating Assets (RNNOA)	40.92%	15.69%	152.31%	621.59%	71.12%	27.50%	53.88%	85.24%	87.70%	40.75%	42.80%
Return on Equity (ROE)	-65.38%	-40.93%	-217.07%	-65.81%	-35.58%	-37.61%	-52.35%	-58.60%	-61.95%	-54.64%	-48.87%
Cash Return on Invested Capital (CROIC)	-35.21%	-33.43%	-92.83%	-626.97%	-187.41%	-52.76%	-80.97%	-156.61%	-105.67%	-131.80%	-121.20%
Operating Return on Assets (OROA)	-61.67%	-39.13%	-181.82%	-52.71%	-12.62%	-28.26%	-41.03%	-39.01%	-51.11%	-45.19%	-39.00%
Return on Assets (ROA)	-59.65%	-38.11%	-180.39%	-52.13%	-11.57%	-27.20%	-39.84%	-37.86%	-49.83%	-44.36%	-38.67%
Return on Common Equity (ROCE)	-65.38%	-40.93%	-217.07%	-65.81%	-35.58%	-37.61%	-52.35%	-58.60%	-61.95%	-54.64%	-48.87%
Return on Equity Simple (ROE_SIMPLE)	-274.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-22	-12	-31	-8.36	-5.93	-5.46	-5.98	-5.98	-5.53	-5.05	-4.58
NOPAT Margin	-248.44%	-153.30%	-506.02%	-102.40%	-91.77%	-81.09%	-81.13%	-75.15%	-82.67%	-61.84%	-55.28%
Net Nonoperating Expense Percent (NNEP)	-13.85%	-8.89%	-35.32%	-19.23%	6.89%	-4.87%	-9.22%	-7.83%	-10.30%	-12.52%	-9.27%
Return On Investment Capital (ROIC_SIMPLE)	-26.32%	-14.83%	-62.89%	-23.63%	-12.30%	-12.03%	-12.00%	-13.45%	-14.76%	-15.99%	-16.22%
Cost of Revenue to Revenue	67.80%	66.74%	239.07%	58.14%	54.50%	48.36%	54.26%	57.24%	51.37%	47.20%	52.28%
SG&A Expenses to Revenue	217.68%	148.72%	155.84%	143.89%	139.89%	123.96%	123.04%	109.51%	119.78%	104.56%	89.93%
R&D to Revenue	111.52%	87.90%	77.67%	42.58%	36.70%	43.53%	38.60%	40.61%	46.94%	36.57%	36.76%
Operating Expenses to Revenue	387.13%	252.26%	583.81%	188.14%	176.60%	167.49%	161.64%	150.12%	166.73%	141.13%	126.69%
Earnings before Interest and Taxes (EBIT)	-32	-17	-45	-20	-3.39	-7.12	-8.76	-8.17	-8.52	-7.56	-6.51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-30	-14	-39	-18	-1.14	-4.94	-6.57	-6.03	-6.35	-5.32	-4.21
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.73	0.56	0.80	0.83	0.17	0.24	0.16	0.35	0.35	0.41	0.65
Price to Tangible Book Value (P/TBV)	1.19	0.90	1.03	1.15	0.21	0.29	0.18	0.39	0.38	0.43	0.66
Price to Revenue (P/Rev)	1.62	1.24	1.17	0.96	0.29	0.40	0.28	0.55	0.45	0.43	0.59
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.26	0.31	0.62	0.60	0.00	0.00	0.00	0.00	0.00	0.12	0.50
Enterprise Value to Revenue (EV/Rev)	0.21	0.42	0.48	0.29	0.00	0.00	0.00	0.00	0.00	0.08	0.31
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.44	-0.33	-0.46	-0.93	-0.63	-0.46	-0.56	-0.63	-0.63	-0.49	-0.52
Leverage Ratio	1.43	1.36	1.60	2.21	1.81	1.63	1.69	1.88	1.67	1.61	1.61
Compound Leverage Factor	1.39	1.32	1.59	2.19	1.65	1.57	1.64	1.82	1.63	1.57	1.59
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-5.18	-6.18	-11.29	-12.67	-11.76	-12.39	-12.05	-12.98	-15.10	-20.66	-21.27
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.46	1.63	1.43	1.06	1.70	1.76	2.12	1.98	1.84	2.48	2.07
Quick Ratio	0.63	0.68	0.52	0.38	0.82	0.82	1.14	1.07	0.87	1.42	1.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	93	85	8.77	-29	5.12	27	1.99	-5.96	0.64	-8.30	-6.16
Operating Cash Flow to CapEx	-108,196.15%	-27,244.16%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.17	0.18	0.25	0.21	0.24	0.27	0.35	0.38	0.40	0.49	0.50
Accounts Receivable Turnover	4.97	5.28	4.77	4.37	4.88	5.63	5.84	5.73	7.68	7.68	5.99
Inventory Turnover	1.03	1.00	1.67	1.79	1.92	1.85	1.45	1.85	2.05	2.29	2.39
Fixed Asset Turnover	1.69	1.62	1.62	1.45	1.31	1.30	1.59	1.67	1.78	1.99	2.19
Accounts Payable Turnover	2.12	2.52	2.82	3.50	3.41	3.48	2.11	2.44	2.62	2.93	2.80
Days Sales Outstanding (DSO)	73.51	69.19	76.57	83.44	74.80	64.87	62.54	63.71	47.55	47.53	60.94
Days Inventory Outstanding (DIO)	354.24	364.75	219.18	204.22	190.19	196.99	251.35	197.34	178.07	159.40	153.04
Days Payable Outstanding (DPO)	172.24	145.02	129.45	104.15	107.05	104.97	172.76	149.50	139.21	124.50	130.14
Cash Conversion Cycle (CCC)	255.51	288.92	166.29	183.51	157.95	156.89	141.12	111.55	86.41	82.43	83.84
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	30	50	26	15	19	18	18	15	13	21	20
Invested Capital Turnover	0.43	0.37	0.73	6.71	1.16	0.80	1.31	1.91	1.81	1.54	1.66
Increase / (Decrease) in Invested Capital	-115	-97	-40	21	-11	-32	-7.96	-0.01	-6.17	3.25	1.59
Enterprise Value (EV)	7.94	15	16	8.94	-21	-16	-24	-14	-12	2.55	9.70
Market Capitalization	61	45	39	29	8.39	11	8.00	16	13	13	18
Book Value per Share	$1.51	$1.20	$0.57	$0.35	$0.47	$13.49	$10.64	$4.37	$3.38	$2.75	$2.40
Tangible Book Value per Share	$0.93	$0.75	$0.44	$0.25	$0.39	$11.40	$9.42	$3.94	$3.11	$2.61	$2.37
Total Capital	83	80	49	35	48	45	50	44	37	32	28
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-53	-30	-23	-20	-29	-27	-32	-30	-25	-10	-8.67
Capital Expenditures (CapEx)	0.03	0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-26	-6.56	-8.92	-18	-11	-8.95	-6.02	-7.09	-6.92	4.42	4.54
Debt-free Net Working Capital (DFNWC)	27	23	14	2.15	19	18	26	22	18	15	13
Net Working Capital (NWC)	27	23	14	2.15	19	18	26	22	18	15	13
Net Nonoperating Expense (NNE)	9.64	4.31	14	12	-2.82	1.40	2.53	1.96	2.78	2.37	1.88
Net Nonoperating Obligations (NNO)	-53	-30	-23	-20	-29	-27	-32	-30	-25	-10	-8.67
Total Depreciation and Amortization (D&A)	2.36	2.82	5.42	2.31	2.24	2.18	2.19	2.14	2.17	2.24	2.30
Debt-free, Cash-free Net Working Capital to Revenue	-68.48%	-17.92%	-26.77%	-59.56%	-37.63%	-32.65%	-20.97%	-24.87%	-24.09%	14.64%	14.61%
Debt-free Net Working Capital to Revenue	72.34%	63.95%	42.09%	6.97%	65.07%	67.40%	89.91%	78.73%	61.75%	49.17%	42.50%
Net Working Capital to Revenue	72.34%	63.95%	42.09%	6.97%	65.07%	67.40%	89.91%	78.73%	61.75%	49.17%	42.50%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($36.00)	($14.40)	($31.20)	($949.80)	($1.15)	($1.99)	($1.59)	($1.46)	($0.76)	($0.64)	($0.54)
Adjusted Weighted Average Basic Shares Outstanding	878.98K	1.13M	1.43M	21.18K	2.69M	3.44M	5.34M	5.45M	10.98M	11.55M	11.99M
Adjusted Diluted Earnings per Share	($36.00)	($14.40)	($31.20)	($949.80)	($1.15)	($1.99)	($1.59)	($1.46)	($0.76)	($0.64)	($0.54)
Adjusted Weighted Average Diluted Shares Outstanding	878.98K	1.13M	1.43M	21.18K	2.69M	3.44M	5.34M	5.45M	10.98M	11.55M	11.99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($949.80)	$0.00	$0.00	$0.00	($1.46)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.11M	1.43M	1.70M	50.12K	3.36M	4.68M	10.18M	11.09M	11.48M	11.78M	13.99M
Normalized Net Operating Profit after Tax (NOPAT)	-18	-11	-16	-8.26	-5.93	-5.46	-5.98	-5.98	-5.53	-5.05	-4.58
Normalized NOPAT Margin	-207.89%	-142.35%	-260.81%	-101.23%	-91.77%	-81.09%	-81.13%	-75.15%	-82.67%	-61.84%	-55.28%
Pre Tax Income Margin	-358.54%	-208.44%	-728.17%	-246.53%	-47.93%	-101.69%	-115.23%	-99.32%	-124.02%	-90.76%	-77.88%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.64%	-0.96%	-2.00%	0.00%	0.00%	-3.52%	-6.50%	-8.04%	-3.90%	-3.59%	-0.93%

Financials Breakdown Chart

Key Financial Trends

Bionano Genomics’ Q2 2026 results show improving revenue and gross margins, but the company remains unprofitable and continues to consume cash. Revenue increased to $8.2 million from $6.7 million in Q1 2026 and $6.7 million in Q2 2025. Gross profit rose to $4.3 million, producing a gross margin of approximately 52.8%, compared with 48.6% in Q1 and 51.7% in the year-ago quarter.

Operating performance has improved from the severe losses reported in 2024, but operating expenses still substantially exceed gross profit. Bionano recorded a $7.2 million operating loss and a $7.4 million net loss in Q2 2026. The net loss improved from $8.3 million in Q1, although it was higher than the restated $6.9 million loss in Q2 2025.

The balance sheet remains a key concern. Cash, restricted cash and short-term investments totaled approximately $10.4 million at June 30, 2026, down sharply from $27.1 million at March 31 and $26.6 million at June 30, 2025. Operating cash flow was negative $4.7 million in Q2, suggesting that additional financing or substantially lower cash usage may eventually be necessary if current trends continue.

Revenue momentum improved: Q2 2026 revenue rose approximately 22% sequentially and 22% year over year to $8.2 million.
Gross margin strengthened: The gross margin increased to about 52.8%, the highest among the comparable 2026 and 2025 quarters provided.
Operating losses narrowed from prior periods: The $7.2 million operating loss was materially better than the $17.0 million loss in Q2 2024 and was slightly better than the $7.8 million loss in Q2 2025.
Quarterly net loss improved sequentially: The net loss declined from $8.3 million in Q1 2026 to $7.4 million in Q2.
Debt repayment reduced obligations: Bionano repaid $10.3 million of debt during Q2, contributing to lower total liabilities and potentially reducing future interest costs.
Investment activity materially affected cash flow: The company generated $13.7 million from investing activities, but this primarily reflected investment maturities and sales exceeding purchases rather than operating profitability.
Liquidity is concentrated in several asset categories: In addition to $3.7 million of cash, Bionano held $6.2 million of short-term investments and $4.4 million of accounts receivable, although not all of these assets are immediately available to fund operations.
Operating cash flow remained negative: Bionano used $4.7 million in operating cash during Q2, following $5.7 million of operating cash burn in Q1 and $4.2 million in Q4 2025.
Liquidity declined significantly: Cash, restricted cash and short-term investments fell by approximately $16.6 million from Q1 2026 and by approximately $16.1 million year over year.
Large accumulated deficit and continuing losses remain: Retained earnings were negative $735.3 million at June 30, while Q2 expenses included $8.5 million of selling, general and administrative costs and $3.0 million of research and development spending.

Investors should also monitor share-count trends. Weighted-average basic shares increased to 11.5 million in Q2 2026 from 3.4 million in the restated Q2 2025 data, although the historical figures are affected by corporate actions and restatements. Continued losses, financing needs and potential dilution remain important risks despite the recent improvement in revenue and gross margin.

11/14/26 11:15 PM ETAI Generated. May Contain Errors.

Bionano Genomics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Bionano Genomics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Bionano Genomics' net income appears to be on a downward trend, with a most recent value of -$26.40 million in 2025, falling from -$23.37 million in 2017. The previous period was -$112.02 million in 2024. View Bionano Genomics' forecast to see where analysts expect Bionano Genomics to go next.

Bionano Genomics' total operating income in 2025 was -$33.34 million, based on the following breakdown:

Total Gross Profit: $13.19 million
Total Operating Expenses: $46.52 million

Over the last 8 years, Bionano Genomics' total revenue changed from $9.51 million in 2017 to $28.51 million in 2025, a change of 199.9%.

In the past 12 quarters, Bionano Genomics' cash and equivalents has ranged from $3.07 million in Q3 2025 to $34.57 million in Q3 2023, and is currently $4.36 million as of their latest financial filing in Q3 2026.

Bionano Genomics had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2017.

Over the last 8 years, Bionano Genomics' book value per share changed from -18.60 in 2017 to 4.37 in 2025.

Related Companies

Financial statements for NASDAQ:BNGO last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bionano Genomics (BNGO) Financials

Financials Breakdown Chart

Key Financial Trends

Bionano Genomics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bionano Genomics (BNGO) Financials

Annual Income Statements for Bionano Genomics

Quarterly Income Statements for Bionano Genomics

Annual Cash Flow Statements for Bionano Genomics

Quarterly Cash Flow Statements for Bionano Genomics

Annual Balance Sheets for Bionano Genomics

Quarterly Balance Sheets for Bionano Genomics

Annual Metrics And Ratios for Bionano Genomics

Quarterly Metrics And Ratios for Bionano Genomics

Financials Breakdown Chart

Key Financial Trends

Bionano Genomics Financials - Frequently Asked Questions

When does Bionano Genomics' fiscal year end?

How has Bionano Genomics' net income changed over the last 8 years?

What is Bionano Genomics' operating income?

How has Bionano Genomics' revenue changed over the last 8 years?

How much cash does Bionano Genomics have?

How much debt does Bionano Genomics have?

How has Bionano Genomics' book value per share changed over the last 8 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools